Foghorn Therapeutics, Inc. (FHTX)
1.87
-0.04
(-1.84%)
USD |
NASDAQ |
Nov 06, 16:00
1.865
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Enterprise Value : -14.68M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | -14.68M |
| November 05, 2026 | -12.63M |
| November 04, 2026 | -1.18M |
| November 03, 2026 | 0.5815M |
| November 02, 2026 | 0.5815M |
| October 30, 2026 | -2.354M |
| October 29, 2026 | -1.767M |
| October 28, 2026 | 0.5815M |
| October 27, 2026 | -4.116M |
| October 26, 2026 | -4.116M |
| October 23, 2026 | -7.051M |
| October 22, 2026 | -6.464M |
| October 21, 2026 | -4.703M |
| October 20, 2026 | -6.464M |
| October 19, 2026 | -14.68M |
| October 16, 2026 | -15.86M |
| October 15, 2026 | -13.51M |
| October 14, 2026 | -15.86M |
| October 13, 2026 | -15.86M |
| October 12, 2026 | -9.987M |
| October 09, 2026 | -7.051M |
| October 08, 2026 | -7.638M |
| October 07, 2026 | -1.767M |
| October 06, 2026 | -8.813M |
| October 05, 2026 | -7.051M |
| Date | Value |
|---|---|
| October 02, 2026 | -5.877M |
| October 01, 2026 | 46.97M |
| September 30, 2026 | 85.13M |
| September 29, 2026 | 82.19M |
| September 28, 2026 | 82.19M |
| September 25, 2026 | 81.02M |
| September 24, 2026 | 86.89M |
| September 23, 2026 | 102.74M |
| September 22, 2026 | 124.47M |
| September 21, 2026 | 119.18M |
| September 18, 2026 | 118.60M |
| September 17, 2026 | 122.12M |
| September 16, 2026 | 120.36M |
| September 15, 2026 | 117.42M |
| September 14, 2026 | 131.51M |
| September 11, 2026 | 135.04M |
| September 10, 2026 | 139.15M |
| September 09, 2026 | 149.72M |
| September 08, 2026 | 159.11M |
| September 04, 2026 | 164.39M |
| September 03, 2026 | 161.46M |
| September 02, 2026 | 179.07M |
| September 01, 2026 | 209.60M |
| August 31, 2026 | 212.54M |
| August 28, 2026 | 227.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anavex Life Sciences Corp. | -11.72M |
| Vaxcyte, Inc. | 8.468B |
| Connect Biopharma Holdings Ltd. | 15.00M |
| Caribou Biosciences, Inc. | -19.99M |
| Arrowhead Pharmaceuticals, Inc. | 7.983B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.191M |
| Revenue (Quarterly) | 16.07M |
| Total Expenses (Quarterly) | 23.26M |
| EPS Diluted (Quarterly) | -0.1018 |
| Gross Profit Margin (Quarterly) | 98.76% |
| Profit Margin (Quarterly) | -44.74% |
| Earnings Yield | -54.62% |
| Normalized Earnings Yield | -50.72 |